(Circulation. 1998;98:2148-2153.)
© 1998 American Heart Association, Inc.
Clinical Investigation and Reports |
ACE (I/D) Genotype as a Predictor of the Magnitude and Duration of the Response to an ACE Inhibitor Drug (Enalaprilat) in Humans
From the University Department of Medicine and Therapeutics, Western Infirmary, Glasgow, Scotland. Dr Ueda is now at the Second Department of Medicine, Yokohama City University, School of Medicine, Yokohama, Japan.
Correspondence to Dr H.L. Elliott, Department of Medicine and Therapeutics, Western Infirmary, Glasgow, G11 6NT, UK. E-mail h.l.elliott{at}clinmed.gla.ac.uk
Background—We have investigated the possible effects of contrasting ACE (I/D) genotypes on the responses to the ACE inhibitor enalaprilat in normotensive men.
Methods and Results—Subjects with DD (n=12) and II (n=11) ACE genotypes received an intravenous infusion of enalaprilat or placebo. Pressor responses to stepwise, incremental doses of angiotensin I were measured at 1 and 10 hours after dosing. The dose required to raise mean blood pressure by 20 mm Hg (PD20) was calculated individually, and the ratio of PD20 during enalaprilat to that during placebo (dose ratio, DR) was used for assessment of the extent of ACE inhibition. The pressor response was significantly attenuated at 1 hour after enalaprilat in both groups, but significant attenuation was evident at 10 hours after dose only in the II subjects. The DRs at both 1 hour (median, 5.43 versus 2.82, P=0.0035) and 10 hours (2.06 versus 0.84, P=0.0008) after enalaprilat were significantly higher in II subjects than in DD subjects.
Conclusions—The effect of enalaprilat was significantly greater and lasted longer in normotensive men homozygous for the II ACE genotype. By multivariate analysis, ACE (I/D) genotype and plasma angiotensin II levels were predictive of >50% of the variation in response to ACE inhibition.
Key Words: angiotensin • enzymes • enalaprilat • genes
This article has been cited by other articles:
 |
|
 |
|
  N. Daneshtalab, R. Z. Lewanczuk, A. S. Russell, and F. Jamali Drug-disease interactions: losartan effect is not downregulated by rheumatoid arthritis. J. Clin. Pharmacol., November 1, 2006; 46(11): 1344 - 1355. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Trevelyan, E W A Needham, A Morris, and R K Mattu Comparison of the effect of enalapril and losartan in conjunction with surgical coronary revascularisation versus revascularisation alone on systemic endothelial function Heart, August 1, 2005; 91(8): 1053 - 1057. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Daneshtalab, R. Z. Lewanczuk, A. Russell, and F. Jamali Rheumatoid Arthritis Does Not Reduce the Pharmacodynamic Response to Valsartan J. Clin. Pharmacol., March 1, 2004; 44(3): 245 - 252. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I Narita, S Goto, N Saito, J Song, K Omori, D Kondo, M Sakatsume, and F Gejyo Renoprotective efficacy of renin-angiotensin inhibitors in IgA nephropathy is influenced by ACE A2350G polymorphism J. Med. Genet., December 1, 2003; 40(12): e130 - 130. [Full Text]
|
|
|
|
 |
|
 X. Li, Y. Du, Y. Du, and X. Huang Correlation of Angiotensin-Converting Enzyme Gene Polymorphism with Effect of Antihypertensive Therapy by Angiotensin-Converting Enzyme Inhibitor Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2003; 8(1): 25 - 30. [Abstract] [PDF]
|
|
|
|
 |
|
 M.R. Abraham, L. J. Olson, M. J. Joyner, S. T. Turner, K. C. Beck, and B. D. Johnson Angiotensin-Converting Enzyme Genotype Modulates Pulmonary Function and Exercise Capacity in Treated Patients With Congestive Stable Heart Failure Circulation, October 1, 2002; 106(14): 1794 - 1799. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. G. H. van der Kleij, P. E. de Jong, R. H. Henning, D. de Zeeuw, and G. Navis Enhanced Responses of Blood Pressure, Renal Function, and Aldosterone to Angiotensin I in the DD Genotype Are Blunted by Low Sodium Intake J. Am. Soc. Nephrol., April 1, 2002; 13(4): 1025 - 1033. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. Kennon, K. Barakat, G. A. Hitman, C. P. Price, P. G. Mills, K. Ranjadayalan, J. Cooper, H. Clark, and A. D. Timmis Angiotensin-converting enzyme inhibition is associated with reduced troponin release in non-ST-elevation acute coronary syndromes J. Am. Coll. Cardiol., September 1, 2001; 38(3): 724 - 728. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Cicoira, L. Zanolla, A. Rossi, G. Golia, L. Franceschini, G. Cabrini, A. Bonizzato, M. Graziani, S. D. Anker, A. J. S. Coats, et al. Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype J. Am. Coll. Cardiol., June 1, 2001; 37(7): 1808 - 1812. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sanada, Y. Higashi, K. Nakagawa, S. Sasaki, I. Kodama, M. Tsuda, N. Nagai, and K. Ohama Relationship between the angiotensin-converting enzyme genotype and the forearm vasodilator response to estrogen replacement therapy in postmenopausal women J. Am. Coll. Cardiol., May 1, 2001; 37(6): 1529 - 1535. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Roden and N. J. Brown Preprescription Genotyping : Not Yet Ready for Prime Time, but Getting There Circulation, March 27, 2001; 103(12): 1608 - 1610. [Full Text] [PDF]
|
|
|
|
 |
|
 C Fatini, R Abbate, G Pepe, B Battaglini, F Gensini, G Ruggiano, G.F Gensini, and R Guazzelli Searching for a better assessment of the individual coronary risk profile. The role of angiotensin-converting enzyme, angiotensin II type 1 receptor and angiotensinogen gene polymorphisms Eur. Heart J., April 2, 2000; 21(8): 633 - 638. [Abstract] [PDF]
|
|
|
|
|
|
T. J. Anderson, E. Elstein, H. Haber, and F. Charbonneau Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study) J. Am. Coll. Cardiol., January 1, 2000; 35(1): 60 - 66. [Abstract] [Full Text] [PDF]
|
|